CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing

34,273 common shares were sold for a transaction value of ~$615,000 at around $17.93 per share on June 4, 2026. The transaction reduced direct holdings by 6.94%, leaving 459,520 shares directly held post-sale.

The Motley Fool • Jun 9, 2026

International Markets and NovoCure (NVCR): A Deep Dive for Investors

Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research • May 4, 2026

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.

Seeking Alpha • May 1, 2026

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 30, 2026

Novocure Reports First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.

Business Wire • Apr 30, 2026

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out

Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.

Investors Business Daily • Apr 30, 2026

Novocure to Report First Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company's financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces.

Business Wire • Apr 1, 2026

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.

Benzinga • Mar 26, 2026

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported.

Business Wire • Mar 26, 2026